Cobimetinib Plus Vemurafenib: A Review in BRAFV600 Mutation-Positive Unresectable or Metastatic Melanoma

被引：0
作者：
Gillian M. Keating
机构：
[1] Springer,
来源：
Drugs | 2016年 / 76卷
关键词：
Metastatic Melanoma; National Comprehensive Cancer Network; Vemurafenib; Dual Therapy; BRAF Inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The MEK inhibitor cobimetinib (Cotellic®) is indicated for the treatment of patients with BRAFV600 mutation-positive unresectable or metastatic melanoma, in combination with the BRAF inhibitor vemurafenib (Zelboraf®). In the pivotal coBRIM trial, previously untreated patients with BRAFV600 mutation-positive unresectable, stage IIIC or stage IV melanoma received cobimetinib 60 mg once daily for the first 21 days of each 28-day cycle plus vemurafenib 960 mg twice daily or vemurafenib alone. Compared with vemurafenib alone, cobimetinib plus vemurafenib significantly prolonged progression-free survival (primary endpoint) and was associated with a significantly higher overall response rate and significantly prolonged overall survival. Cobimetinib plus vemurafenib had a manageable tolerability profile. In conclusion, cobimetinib plus vemurafenib is a valuable option for use in BRAFV600 mutation-positive unresectable or metastatic melanoma.
引用
收藏
页码：605 / 615
页数：10
相关论文
共 124 条
[1]  
Dossett LA(2015)BRAF and MEK inhibition in melanoma Expert Opin Drug Saf. 14 559-570
[2]  
Kudchadkar RR(2014)Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma Oncotarget. 5 10206-10221
[3]  
Zager JS(2010)RG7204 (PLX4032), a selective BRAF Cancer Res. 70 5518-5527
[4]  
Spagnolo F(2010) inhibitor, displays potent antitumor activity in preclinical melanoma models J Transl Med. 8 39-759
[5]  
Ghiorzo P(2008)Differential sensitivity of melanoma cell lines with Mol Cancer Res. 6 751-421
[6]  
Queirolo P(2012) mutation to the specific Raf inhibitor PLX4032 ACS Med Chem Lett. 3 416-219
[7]  
Yang H(2012)BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells Cancer Res. 72 210-3099
[8]  
Higgins B(2012)Novel carboxamide-based allosteric MEK inhibitors: discovery and optimization efforts toward XL518 (GDC-0973) Clin Cancer Res. 18 3090-4054
[9]  
Kolinsky K(2013)Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition Mol Pharm. 10 4046-111
[10]  
Søndergaard JN(2014)Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor Cancer Chemother Pharmacol. 73 103-374
12345678910